A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors

BACKGROUND: Expressed on activated T and natural killer cells, 4-1BB/CD137 is a costimulatory receptor that signals a series of events resulting in cytokine secretion and enhanced effector function. Targeting 4-1BB/CD137 with agonist antibodies has been associated with tumor reduction and antitumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Ezra E. W., Pishvaian, Michael J., Shepard, Dale R., Wang, Ding, Weiss, Jared, Johnson, Melissa L., Chung, Christine H., Chen, Ying, Huang, Bo, Davis, Craig B., Toffalorio, Francesca, Thall, Aron, Powell, Steven F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894203/
https://www.ncbi.nlm.nih.gov/pubmed/31801624
http://dx.doi.org/10.1186/s40425-019-0815-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894203/
https://www.ncbi.nlm.nih.gov/pubmed/31801624
http://dx.doi.org/10.1186/s40425-019-0815-6

Ejemplares similares